Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. ESMO-MCBS
  4. ESMO-MCBS for Solid Tumours

ESMO-MCBS Scorecards

ESMO MCBS 1000x150

The ESMO-MCBS Scorecards provides a centralised location of cancer medicines approved by the European Medicines Agency and the US Food and Drug Administration that have been scored and published by ESMO.

ESMO-MCBS scores are based on peer reviewed clinical trial reports. They are generated using a validated standard methodology and are reviewed by a team of clinicians and statisticians before publication. ESMO-MCBS scores should be interpreted in the context of an evolving treatment landscape, in connection with clinical practice guidelines.

ESMO-MCBS Scores
Number of studies
Non-curative setting
5 22
4 135
3 161
2 55
1 24
NEB 4
Curative setting
A 59
C 3
NEB 3
ESMO-MCBS Scores by tumour type
Non-curative setting
Brain Tumours 4
Breast Cancer 39
Endocrine Tumours 23
Gastrointestinal Cancers 76
Genitourinary Cancers 71
Gynaecological Malignancies 38
Head and neck cancer 12
Non-cancerous soft-tissue tumour 3
Sarcoma 13
Skin Cancers 29
Thoracic Malignancies 86
TMB-H solid tumours 1
Tumour agnostic 6
Curative setting
Brain Tumours 2
Breast Cancer 9
Endocrine Tumours 0
Gastrointestinal Cancers 17
Genitourinary Cancers 5
Gynaecological Malignancies 1
Head and neck cancer 1
Non-cancerous soft-tissue tumour 0
Sarcoma 3
Skin Cancers 14
Thoracic Malignancies 13
TMB-H solid tumours 0
Tumour agnostic 0

The ESMO-MCBS Scorecards

reset selection
Evaluation form 1  For new approaches to adjuvant therapy or new potentially curative therapies
Evaluation form 2a For therapies that are not likely to be curative with primary endpoint of OS with separate sheets for:
Evaluation form 2b For therapies that are not likely to be curative with primary endpoint PFS with separate sheets for:
Evaluation form 2c  For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies
Evaluation form 3  For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR.
To evaluate ESMO-MCBS score adjustments based on quality of life .

My watchlist

    Tested Agent(s) Combined Agent(s) Control Arm Therapeutic Indication Tumour Type Tumour Sub-type Tumour Sub-group Trial Name Ref. Score Scorecard Scorecard
    Epirubicin, 5-FU, Cisplatin + surgery - Surgery Peri-operative resectable gastric or gastroesophageal junction adenocarcinoma MAGIC
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma - MAGIC

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    5-FU + cisplatin + surgery - Surgery Peri-operative resectable gastric or gastroesophageal junction adenocarcinoma FRE-FNCLCC-94012
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma - FRE-FNCLCC-94012

    A

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F1

      A
    Ramucirumab Paclitaxel Paclitaxel + placebo Advanced gastric cancer or gastroesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine ChT RAINBOW
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma - RAINBOW

    2

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      2
    Ramucirumab - Placebo Treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine ChT, when treatment in combination with paclitaxel is not appropriate REGARD
    Gastrointestinal Cancers
    		 Gastric or gastroesophageal junction adenocarcinoma - REGARD

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    FOLFIRINOX - Gemcitabine First-line metastatic pancreatic cancer in patients with good performance status PRODIGE 4/ACCORD 11
    Gastrointestinal Cancers
    		 Pancreatic cancer - PRODIGE 4/ACCORD 11

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Nab-paclitaxel Gemcitabine Gemcitabine Nab-paclitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas MPACT
    Gastrointestinal Cancers
    		 Pancreatic cancer - MPACT

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Erlotinib Gemcitabine Gemcitabine + placebo Erlotinib in combination with gemcitabine for the treatment of patients with metastatic pancreatic cancer PA.3
    Gastrointestinal Cancers
    		 Pancreatic cancer - PA.3

    1

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      1
    Bevacizumab Combination chemotherapy Combination chemotherapy In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix GOG 240
    Gynaecological Malignancies
    		 Cervical Cancer - GOG 240

    3

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      3
    Bevacizumab Chemotherapy Paclitaxel or topotecan or liposomal doxorubicin In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube,or primary peritoneal cancer who received ≤2 prior ChT regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents AURELIA
    Gynaecological Malignancies
    		 Ovarian Cancer - AURELIA

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Bevacizumab Paclitaxel + carboplatin Paclitaxel + carboplatin In combination with carboplatin and paclitaxel for the front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer ICON7
    Gynaecological Malignancies
    		 Ovarian Cancer - ICON7

    1

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      1
    Bevacizumab Gemcitabine + carboplatin Gemcitabine + carboplatin In combination with carboplatin and gemcitabine for treatment of adult patients with first recurrence platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents OCEANS
    Gynaecological Malignancies
    		 Ovarian Cancer - OCEANS

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Bevacizumab Carboplatin + paclitaxel Paclitaxel + carboplatin (6 cycles) Front-line treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. GOG-0218
    Gynaecological Malignancies
    		 Ovarian Cancer - GOG-0218

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Niraparib - Placebo Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChT ENGOT-OV16/NOVA
    Gynaecological Malignancies
    		 Ovarian Cancer BRCA-mut ENGOT-OV16/NOVA

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Niraparib - Placebo Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChT ENGOT-OV16/NOVA
    Gynaecological Malignancies
    		 Ovarian Cancer HRD+, non BRCA-mut ENGOT-OV16/NOVA

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Niraparib - Placebo Patients with platinum-sensitive relapsed high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) to platinum-based ChT ENGOT-OV16/NOVA
    Gynaecological Malignancies
    		 Ovarian Cancer Non BRCA-mut ENGOT-OV16/NOVA

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Trabectedin Pegylated liposomal doxorubicin Pegylated liposomal doxorubicin In combination with PLD for the treatment of patients with relapsed platinum-sensitive ovarian cancer OVA-301
    Gynaecological Malignancies
    		 Ovarian Cancer Platinum sensitive OVA-301

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Trabectedin Pegylated liposomal doxorubicin Pegylated liposomal doxorubicin In combination with PLD for the treatment of patients with relapsed platinum-sensitive ovarian cancer OVA-301
    Gynaecological Malignancies
    		 Ovarian Cancer - OVA-301

    3

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      3
    Olaparib - Placebo Maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy (Phase II) Study 19
    Gynaecological Malignancies
    		 High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer BRCA-mut Study 19

    2

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      2
    Cediranib Chemotherapy Platinum-based chemotherapy + placebo and placebo maintenance Platinum-sensitive relapsed ovarian cancer ICON 6
    Gynaecological Malignancies
    		 Ovarian Cancer - ICON 6

    1

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      1
    Pembrolizumab - Docetaxel EMA: Pembrolizumab is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab. (2 mg/kg and 10mg/kg pooled data). FDA: Pembrolizumab for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS greater than or equal to 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving pembrolizumab. KEYNOTE-010
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 ≥1% KEYNOTE-010

    A

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      5

      A
    Pembrolizumab - Docetaxel EMA: Pembrolizumab is indicated for the treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express PD-L1 and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received approved therapy for these mutations prior to receiving pembrolizumab. (2 mg/kg and 10mg/kg pooled data). FDA: Pembrolizumab for the treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression (Tumor Proportion Score [TPS] greater than or equal to 50%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC. KEYNOTE-010
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer PD-L1 ≥50% KEYNOTE-010

    A

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a/F1
      5

      A
    Nivolumab - Docetaxel Locally advanced or metastatic squamous NSCLC after prior ChT CheckMate 017
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - Squamous cell - CheckMate 017

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Nivolumab - Docetaxel Locally advanced or metastatic squamous NSCLC after prior ChT CheckMate 057
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer - CheckMate 057

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Erlotinib - Carboplatin gemcitabine Locally advanced or metastatic NSCLC with EGFR activating mutations OPTIMAL, CTONG-0802
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ OPTIMAL, CTONG-0802

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Erlotinib - Platinum-based chemotherapy doublet Locally advanced or metastatic NSCLC with EGFR activating mutations EURTAC
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ EURTAC

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Gefitinib - Carboplatin + paclitaxel Treatment of adult patients with locally advanced or metastatic NSCLC with activating mutations of EGFR tyrosine kinase. IPASS
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ IPASS

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Afatinib - Cisplatin + pemetrexed As monotherapy for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s) LUX - Lung 3
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ LUX - Lung 3

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Afatinib - Cisplatin + pemetrexed As monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s) - Del19/L858R pre-planned subgroup analysis LUX - Lung 3
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ LUX - Lung 3

    5

    PRELIMINARY SCORE

    • OS

    ADJUSTMENTS

    SCORE

    • F2a
      5
    Osimertinib - Platinum/pemetrexed Osimertinib used as monotherapy for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. AURA3
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer EGFR+ (T790M ) AURA3

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4
    Crizotinib - Chemotherapy Treatment of adults with previously treated anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) PROFILE 1007
    Thoracic Malignancies
    		 Non-small-cell Lung Cancer ALK+ PROFILE 1007

    4

    PRELIMINARY SCORE

    • PFS

    ADJUSTMENTS

    SCORE

    • F2b
      4

    This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    Customise settings

    • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.